CRISPR ( Clustered Regularly Interspaced Short Palindromic Repeats)
CRISPR based
detection systems are poised to emerge as the next-generation point-of-care
(POC) diagnostic platform, and have the potential to marry the advantages of
RT-PCR (sensitive/specific) and rapid test kits (RTKs) (fast turnaround,
user-friendly). These systems also circumvent the deficiencies of both RT-PCR
(long turnaround, equipment/trained user requirement) and RTKs (low
sensitivity). These POC platforms play a crucial role for effective medical
intervention and transmission control of infectious diseases such as COVID-19.
For
these systems to be widely adopted clinically, developments have been made to
enhance the thermal compatibility of CRISPR with isothermal amplification
assays, towards a one-step, one-pot platform. The COVID-19 pandemic has
strained healthcare systems. Sensitive, specific, and timely COVID-19 diagnosis
is crucial for effective medical intervention and transmission control. RT-PCR
is the most sensitive/specific, but requires costly equipment and trained
personnel in centralized laboratories, which are inaccessible to
resource-limited areas. Antigen rapid tests enable point-of-care (POC)
detection but are significantly less sensitive/specific. CRISPR-Cas systems are
compatible with isothermal amplification and dipstick readout, enabling
sensitive/specific on-site testing. However, improvements in sensitivity and
workflow complexity are needed to spur clinical adoption. We outline the
mechanisms/strategies of major CRISPR-Cas systems, evaluate their on-site
diagnostic capabilities, and discuss future research directions.
Comments
Post a Comment